（旧大阪市立大学）
大阪公立大学　大学院医学研究科　臨床腫瘍学
お問い合わせサイトマップリンクアクセス
すてーじ
ホーム > 研究と業績

2018

英文

  1. Yoshimura N, Tada T, Matsumoto Y, Sawa K, Yoshimoto N, Suzumura T, Tanaka H, Mitsuoka S, Kimura T, Tamiya T, Hirashima T, Kawaguchi T, Kudoh S, Hosono M, Hirata K. Dose escalation study of concurrent chemoradiotherapy with the use of involved-field conformal radiotherapy and accelerated hyperfractionation in combination with cisplatin and vinorelbine chemotherapy for stage Ⅲ non-small cell lung cancer. Am J Clin Oncol 2018;41:967-971.
  2. Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K. B7-H3 negatively modulates CTL-mediated cancer immunity. Clin Cancer Res 2018;24:2653-2664.
  3. Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Ito A, Nakagawa K. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol 2018;13:97-105.
  4. Date E, Okamoto K, Fumita S, Kaneda H. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer. Invest New Drugs 2018;36:350-353.
  5. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018;4:374-378.

和文

  1. 光岡茂樹. 肺癌と免疫(喫煙・遺伝子変異・ネオアンチゲン). がん免疫療法 2018;2:6-9.

2017

英文

  1. Sawa K, Koh Y, Kawaguchi T, Kambayashi S, Asai K, Mitsuoka S, Kimura T, Yoshimura N, Yoshimoto N, Kubo A, Saka H, Matsumura A, Wanibuchi H, Yamamoto N, Nishiyama N, Hirata K. PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort. Lung Cancer. 2017;112:96-101.
  2. Yoshimura N, Tada T, Matsumoto Y, Sawa K, Yoshimoto N, Suzumura T, Tanaka H, Mitsuoka S, Kimura T, Tamiya T, Hirashima T, Kawaguchi T, Kudoh S, Hosono M, Hirata K. Dose Escalation Study of Concurrent Chemoradiotherapy With the Use of Involved-field Conformal Radiotherapy and Accelerated Hyperfractionation in Combination With Cisplatin and Vinorelbine Chemotherapy for Stage III Non-small Cell Lung Cancer: The Final Report. Am J Clin Oncol. 2017;17.
  3. Matsumoto Y, Kawaguchi T, Yamamoto N, Sawa K, Yoshimoto N, Suzumura T, Watanabe T, Mitsuoka S, Asai K, Kimura T, Yoshimura N, Kuwae Y, Hirata K. Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer. Intern Med. 2017;56:2325-2328.

2016

英文

川口 知哉

  1. Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Serizawa M, Tamiya A, Shimizu S, Yoshimoto N, Kubo A, Isa S, Saka H, Matsumura A. Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors : Japan Molecular Epidemiology for Lung Cancer Study. J Clin Oncol 2016;34:2247-2257.
  2. Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K. Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lun cancer with wild-type EGFR. Expert Opin Pharmacother 2016;17:193-203.
  3. Sawa K, Kawaguchi T, Mitsuoka S, Kusutani N, Hirata K. Pneumonitis with nonspecific interstitial pneumonia pattern caused by nivolumab in a patient with metastatic melanoma. Internal Medicine Open access 2016.

鈴村 倫弘

  1. Ota T, Suzumura T, Sugiura T, Hasegawa Y, Yonesaka K, Makihara M, Tsukuda H, Tada T, Fukuoka M. Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer. Clin Case Rep 2016;4:481-485.
  2. Hasegawa Y, Ota T, Tsukuda H, Suzumura T, Fukuoka M. Drug-induced Pneumonitis Following the Administration of TAS-102. Intern Med. 2016;55:2855-2859.
  3. Ota T, Nakano M, Tanaka N, Suzumura T, Miyatake N, Hasegawa Y, Ozaki T, Tsukuda H, Fukuoka M. Abdominal pain under immunosuppressive conditions. Clev Clin J Med. 2016;83:874-875.

吉本 直樹

  1. Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, Satouchi M, Hida T, Yoshimura N, Kozuki T, Imamura F, Kiura K, Okamoto H, Sawa T, Tamura T. JCOG0605 investigators. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605) : a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2016;17:1147-1157.
  2. Yoshimoto N, Kawaguchi T, Isa S, Shimizu S, Tamiya A, Asai K, Kudoh S, Hirata K. Molecular Epidemiological Study on Passive Smoking and Estrogen Receptor Expression in Never-smokers with Non-small Cell Lung Cancer. Osaka City Medical Journal 2016;62:77-84.

2015

英文

日野 雅之

  1. Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. J Infect Chemother 21:16-22, 2015

川口 知哉

  1. Tomoya Kawaguchi, Masahiko Ando, and Akihito Kubo. Reply to G. Spitzer and M.A. Socinski, F. Zhou et al, and B. Biswas. J Clin Oncol 33: 526-527, 2015
  2. Shun-ichi Isa, Yu Kurahara, Satomi Yamamoto, Akihiro Tamiya, Naoki Omachi, Kazuhiro Asami, Kyouichi Okishio, Tomoki Utsumi, Norimasa Ito, Hyung-Eun Yoon, Akihide Matsumura, Shinji Atagi, and Tomoya Kawaguchi Molecular Analysis of Human Papillomavirus in Never-Smokers with Non-Small Cell Lung Cance, ONCOLOGY LETTERS 9: 927-929, 2015
  3. Masaru Watanabe, Tomoya Kawaguchi, Shun-ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Hideo Saka, Sadanori Takeo, Hirofumi Adachi, Tsutomu Tagawa, Seiichi Kakegawa, Motohiro Yamashita, Kazuhiko Kataoka, Yukito Ichinose, Yukiyasu Takeuchi, Kazuhiro Sakamoto, Akihide Matsumura, Yasuhiro Koh. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small-cell lung cancer patients with an EGFR-activating mutation using picodroplet digital PCR. Clinical Cancer Res 21, 3552-60, 2015
  4. Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, Satomi Yamamoto, Shun-ichi Isa, Hideo Saka, Akihito Kubo, Tomoya Kawaguchi, Minoru Takada, Rafael Rosell, Takayasu Kurata, Sai-Hong Ignatius Ou. The role of smoking status on the progression-free survival of non-small-cell lung cancer patients harboring activating epidermal growth factor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor. A meta-analysis of prospective randomized trials. TheOncologist 2015;20:1–9
  5. Sugitani A, Asai K, Kojima K, Eguchi Y, Kawaguchi T, Ohsawa M, Hirata K. Primary Pleural Synovial Sarcoma Treated with Pazopanib. Intern Med 54:2051-5, 2015
  6. Takehito Shukuya, Takeharu Yamanaka, Takashi Seto, Haruko Daga, Koichi Goto, Hideo Saka, Shunichi Sugawara, Toshiaki Takahashi, Soichiro Yokota, Hiroyasu Kaneda, Tomoya Kawaguchi, Seisuke Nagase, Tetsuya Oguri, Yasuo Iwamoto, Takashi Nishimura, Yoshihiro Hattori, Kazuhiko Nakagawa, Yoichi Nakanishi, Nobuyuki Yamamoto. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised phase 3 study. Lancet Oncology in press
  7. Naoki Omachi, Tomoya Kawaguchi, Shigeki Shimizu, Tomohisa Okuma, Masanori Kitaichi, Shinzi Atagi, Hyungeun Yoon M., Akihide Matsumura Life-threatening and rapidly growing teratoma in the anterior mediastinum Internal Medicine in press
  8. Toshiya Maekura, Shigeki Shimizu, Tomoya Kawaguchi, Masahiro Morimoto, Tomohisa Okuma, Hideo Matsui, Tadaaki Eimoto, Shinji Atagi. Primary Intravascular Synovial Sarcoma of the Pulmonary Artery Masquerading as Intimal Sarcoma: Report of a case with favorable response to ifosfamide chemotherapy plus palliative radiation therapy Internal Medicine in press

光岡 茂樹

  1. Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, Suzumira T, Matusura K, Tochino Y, Asai K, Kimura T, Kawaguchi T, Hirata K. Phase Ⅱ study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. Lung Cancer 2015;90:65-70.

鈴村　倫弘

  1. Ota T, Tsukuda H, Tokunaga M, Nishida N, Hasegawa Y, Suzumura T, Fukuoka M.Catheter detachment. Oxf Med Case Reports 2015;2015:292-293.
  2. Toshiyuki N, Kimura T, Suzumura T, Yoshimoto N, Oka T, Yamamoto N, Matsuura K, Mitsuoka S, Asai K, Tochino Y, Yoshimura N, Kawaguchi T, Kudoh S, Matsuoka T, Ohsawa M, Hirata K. The macroscopic appearance of computed tomography-guided needle biopsy specimens correlates with tumor metastasis in non-small cell lung cancer. Osaka City Med J 2015;61:105-112.

吉村 成央

  1. Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, Suzumura T, Matsuura K, Tochino Y, Asai K, Kimura T, Kawaguchi T, Hirata K. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. Lung Cancer 90: 65-70, 2015

和文

日野 雅之

  1. 岡村浩史, 中根孝彦, 藤野恵三, 康　史郎, 吉村卓朗, 西本光孝, 林　良樹, 康　秀男, 中尾吉孝, 中前博久, 日野雅之. 骨髄異形成症候群の同種造血幹細胞移植後再発に合併した冷式自己免疫性溶血性貧血. 臨床血液 2015;56:412-417.

工藤 新三

  1. 工藤新三. 非小細胞肺がん. 編集委員会編集. 入門腫瘍内科学. 改訂第2版. 東京：篠原出版新社, 2015.pp.173-177.

2014

英文

日野 雅之

  1. Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H, Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y.　Prospectively Isolated Human Bone marRow Cell-Derived MSCs Support Primitive Human CD34-Negative Hematopoietic Stem Cells.　Stem Cells. in press
  2. Nakamae M, Nakamae H, Koh S, Koh H, Nishimoto M, Nakashima Y, Nakane T, Hirose A, Hino M. Prognostic value and clinical implication of serum ferritin levels following allogeneic hematopoietic cell transplantation. Acta Haematol 133:310-316, 2014
  3. Nishimoto M, Nakamae H, Nakamae M, Hirose A, Hagihara K, Koh H, Nakane T, Terada Y, Hino M. Feasibility of umbilical cord blood transplantation with a myeloablative, reduced toxicity-conditioning regimen. Bone Marrow Transplant 49:980-981, 2014
  4. Kodera Y, Yamamoto K, Harada M, Morishima Y, Dohy H, Asano S, Ikeda Y, Nakahata T, Imamura M, Kawa K, Kato S, Tanimoto M, Kanda Y, Tanosaki R, Shiobara S, Kim SW, Nagafuji K, Hino M, Miyamura K, Suzuki R, Hamajima N, Fukushima M, Tamakoshi A Halter J, Schmitz N, Niederwieser D, Gratwohl A. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant. 49;195-200, 2014
  5. Tamori A, Hino M, Kawamura E, Fujii H, Uchida-Kobayashi S, Morikawa H, Nakamae H, Enomoto M, Murakami Y, Kawada N. A prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol 29:1715-21, 2014
  6. Kuroda J, Shimura Y, Ohta K, Tanaka H, Shibayama H, Kosugi S, Fuchida S, Kobayashi M, Kaneko H, Uoshima N, Ishii K, Nomura S, Taniwaki M, Takaori-Kondo A, Shimazaki C, Tsudo M, Hino M, Matsumura I, Kanakura Y. Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. Int J Hematol. 99:441-9, 2014
  7. Aimoto M, Koh H, Katayama T, Okamura H, Yoshimura T, Koh S, Nanno S, Nishimoto M, Hirose A, Nakamae M, Nakane T, Nakamae H, Kakeya H, Hino M. Diagnostic performance of serum high-sensitivity procalcitonin and serum C-reactive protein tests for detecting bacterial infection in febrile neutropenia. Infection 42:971-9, 2014

工藤 新三

  1. Harada T, Hamada A, Shimokawa M, Takayama K, Kudoh S, Maeno K, Saeki S, Miyawaki H, Moriyama A, Nakagawa K, Nakanishi Y. A Phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer. Jpn J Clin Oncol. 2014 Feb;44(2):127-33 2014
  2. Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III Study Comparing Amrubicin Plus Cisplatin With Irinotecan Plus Cisplatin in the Treatment of Extensive-Disease Small-Cell Lung Cancer: JCOG 0509. J Clin Oncol. 2014 Mar 17. [Epub ahead of print]

川口 知哉

  1. Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami, Yoshio Okano, Masaaki Fukuda, Hideyuki Nakagawa, Hidenori Ibata, Toshiyuki Kozuki, Tateo Endo, Atsuhisa Tamura, Mitsuhiro Kamimura, Kazuhiro Sakamoto, Michihiro Yoshimi, Yoshifumi Soejima, Yoshio Tomizawa, Shun-ichi Isa, Minoru Takada, Hideo Saka, Akihito Kubo. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small cell lung cancer: Docetaxel and Erlotinib Lung cancer TriAl (DELTA). J Clin Oncol 32: 1902-1908, 2014
  2. A Tamiya, A Matsumura, T Tsuji, M Morimoto, K Asami, K Okishio, S Shimizu, HE Yoon, S Atagi, M Akira, M Kitaichi, T Kawaguchi　A pilot study of cisplatin and etoposide with or without radiotherapy for advanced malignant thymoma. Anticancer Research 34: 2023-2028 , 2014

鈴村　倫弘

  1. Suzumura T, Yonesaka K, Tsukuda H, Fukuoka M ; 1. Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia ; BMJ Case Reports 2014

和文

日野 雅之

  1. 掛屋 弘, 山田康一, 中家清隆, 滝沢恵津子, 岡田恵代, 藤田明子, 中村安孝, 安部順子, 広瀬朝生, 金子幸弘, 日野雅之. 当院における臨床分離緑膿菌のカルバペネム系抗菌薬に対する薬剤感受性の比較. Jpn J Antibiot. 67(4):241-8, 2014
  2. 日野雅之.　APLの臨床と最新治療.　日本検査血液学会雑誌 15:357-363, 2014
  3. 稲葉 晃子, 康 秀男, 中嶋 康博, 西本 光孝, 林 良樹, 岡村 浩史, 井上 敦司, 南野 智, 中根 孝彦, 下野 太郎, 中前 博久, 日野 雅之. 髄液中特異的IgM抗体が診断に有用であった臍帯血移植後トキソプラズマ脳症. 臨床血液 55, 456-460, 2014
  4. 西本 光孝, 康 秀男, 備後 真登, 吉田 全宏, 南野 智, 林 良樹, 中根 孝彦, 中前 博久, 下野 太郎, 日野 雅之. 化学療法中の急性膵炎に続発して可逆性後頭葉白質脳症を発症した急性単球性白血病. 臨床血液 55, 552-557, 2014
  5. 吉村 卓朗, 中根 孝彦, 亀崎 豊実, 稲葉 晃子, 西本 光孝, 向井 悟, 坂部 真奈美, 大澤 政彦, 藤野 惠三, 康 秀男, 中尾 吉孝, 中前 博久, 日野 雅之. Evans症候群罹患後20年を経過して発症した溶血発作を伴うdiffuse large B-cell lymphoma. 臨床血液 55, 546-551, 2014
  6. 宮村耕一、岡本真一郎、薄井紀子、日野雅之、赤司浩一、中世古知昭、高橋直人、中谷　中、高橋啓太、登　勉、直江和樹. キャリブレーターによる国際標準値変換を可能とするMajor BCR-ABL mRNA測定キットの臨床性能評価. 臨床血液 55, 534-540, 2014

2013

英文

日野 雅之

  1. Nishimoto M, Nakamae H, Koh H, Nakane T, Nakamae M, Hirose A, Hagihara K, Nakao Y, Terada Y, Ohsawa M, Hino M. Risk factors affecting cardiac left-ventricular hypertrophy and systolic and diastolic function in the chronic phase of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 48: 581-62, 2013
  2. Okamura H, Hayashi Y, Nakamae H, Shiomi S, Nishimoto M, Koh H, Nakane T, Hino M. Use of per rectal portal scintigraphy to detect portal hypertension in sinusoidal obstructive syndrome following unrelated cord blood transplantation. Acta Haematol 130, 83-86, 2013
  3. Kim SW, Yoon SS, Suzuki R, Matsuno Y, Yi HG, Yoshida T, Imamura M, Wake A, Miura K, Hino M, Ishikawa T, Kim JS, Maeda Y, Lee JJ, Kang HJ, Lee HS, Lee JH, Izutsu K, Fukuda T, Kim CW, Yoshino T, Ohshima K, Nakamura S, Nagafuji K, Suzumiya J, Harada M, Kim CS. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia 27:1394-1397, 2013
  4. Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M, Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H, Morishima Y, Sakamaki H, Suzuki R. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy. Biol Blood Marrow Transplant 19, 1183-1189, 2013
  5. Koh H, Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N, Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A, Masaoka T. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan. J Infect ChemotherJ 19:1126-34, 2013
  6. Shinohara Y, Takahashi N, Nishiwaki K, Hino M, Kashimura M, Wakita H, Hatano Y, Hirasawa A, Nakagawa Y, Itoh K, Masuoka H, Aotsuka N, Matsuura Y, Takahara S, Sano K, Kuroki J, Hata T, Nakamae H, Mugitani A, Nakane T, Miyazaki Y, Niioka T, Miura M, Sawada K. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction. Haematologica. 98:1407-13, 2013
  7. Nishimoto M, Nakamae H, Kho K-R, Kosaka S, Matsumoto K, Morita K, Kho H, Nakane T, Ohsawa M, Hino M. Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for isolated central nervous system blast crisis of chronic myelogenous leukemia. Acta Haematol 130:111-114, 2013
  8. Nakagawa Y, Suzuki K, Ohta K, Hino M, Ohyashiki K, Kanamaru A, Tamura K, Urabe A, Masaoka T. Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia. J Infect Chemother 19:103-11, 2013
  9. Yoshimura T, Nakane T, Hirose A, Koh H, Nakamae M, Aimoto M, Nishimoto M, Hayashi Y, Terada Y, Nakamae H, Hino M. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors. Osaka City Med J 59:9-21, 2013
  10. Nishimoto M, Nakamae H, Watanabe K, Koh H, Nakane T, Ohsawa M, Arakawa T, Hino M. Successful treatment of both acute leukemia and active Crohn's disease after allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and busulfan: a case report. Transplant Proc 45:2854-2857, 2013
  11. Aimoto M, Yamane T, Shiomoto K, Sakamoto C, Nakashima Y, Koh H, Nakane T, Takeoka Y, Hirose A, Nakamae M, Hagihara K, Terada Y, Nakao Y, Nakamae H, Hino M, Miyata S. Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies. Int J Hematol 98:472-477, 2013

工藤 新三

  1. Nagata M, Kudoh S, Mitsuoka S, Suzumura T, Umekawa K, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Hirata K Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations. Osaka City Med J. 2013 Jun;59(1):45-52 2013
  2. Yoshimura N, Okishio K, Mitsuoka S, Kimura T, Kawaguchi T, Kobayashi M, Hirashima T, Daga H, Takeda K, Hirata K, Kudoh S Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol. 2013 Jan;8(1):96-101. 2013
  3. Yoshioka H, Okamoto I, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Atagi S, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Nakanishi Y, Nakagawa K. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol. 2013 Feb 4. [Epub ahead of print] 2013
  4. Nagata M, Kimura T, Suzumura T, Kira Y, Nakai T, Umekawa K, Tanaka H, Matsuura K, Mitsuoka S, Yoshimura N, Oka T, Kudoh S, Hirata K. C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. Clin Med Insights Oncol. 2013;7:31-9. 2013
  5. Yoshimura N, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Ichimaru Y, Hirata K, Kudoh S. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small cell lung cancer. Am J Clin Oncol. 2013 Apr;36(2):105-9 2013
  6. Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013 Mar 13;3(3) 2013
  7. Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, Kira Y, Hirata K. Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. BMC Res Notes. 2013 Apr 8;6:139 2013
  8. Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L. J Thorac Oncol. 2013 Jun;8(6):753-8. 2013
  9. Umekawa K, Kimura T, Kudoh S, Suzumura T, Nagata M, Mitsuoka S, Matsuura K, Oka T, Yoshimura N, Kira Y, Hirata K Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs. Osaka City Med J. 2013 Jun;59(1):53-60. 2013

川口 知哉

  1. Tomoya Kawaguchi, Masahiko Ando, Norimasa Ito, Shun-ichi Isa, Akihiro Tamiya, Shigeki Shimizu, Hideo Saka, Akihito Kubo, Yasuhiro Koh, Akihide Matsumura. Rationale and design of JME study: Japan Molecular Epidemiology for lung cancer study. Clinical Lung Cancer 14: 596-600, 2013
  2. Naruo Yoshimura, Kyoichi Okishio, Shigeki Mitsuoka, Tatsuo Kimura, Tomoya Kawaguchi, Masaji Kobayashi, Tomonori Hirashima, Haruko Daga, Koji Takeda, Kazuto Hirata and Shinzoh Kudoh. Prospective Assessment of Continuation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Pemetrexed. J Thoracic Oncol 8: 96-101, 2013

中尾 吉孝

  1. Nishimoto M. Nakamae H. Koh H. Nakane T. Nakamae M. Hirose A. Hagihara K. Nakao Y. Terada Y. Ohsawa M. Hino M. Risk factors affecting cardiac left-ventricular hypertrophy and systolic and diastolic function in the chronic phase of allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 2013;48:581-586.
  2. Aimoto M. Yamane T. Shiomoto K. Sakamoto C. Nakashima Y. Koh H. Nakane T. Takeoka Y. Hirose A. Nakamae M. Hagihara K. Terada Y. Nakao Y. Nakamae H. Hino M. Miyata S.Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical 　density of anti-platelet factor 4/heparin antibodiesInt J Hematol. 2013 Oct;98(4):472-7.

吉村 成央

  1. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. 共（筆頭） 2013 J ThoracOncol.8(1):96-101.
  2. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small-cell lung cancer 共（筆頭） 2013 Am J Clin Oncol. 36(2):105-9.

和文

日野 雅之

  1. 中前博久、西本光孝、徳和目篤史、日野雅之. 消化管急性移植片対宿主病に対するベクロメタゾンプロピオン酸エステル製剤の有効性. 臨床薬理の進歩 93-98, 2013
  2. 南野　智、中前博久、桑村幸信、石村栄治、坂部真奈美、稲葉晃子、康　史朗、吉村卓朗、西本光孝、林　良樹、寺田芳樹、中根孝彦、康　秀男、中尾吉孝、大澤政彦、日野雅之. 管内増殖性糸球体腎炎を合併した血管免疫芽球性T細胞性リンパ腫. 臨床血液　54:658-663, 2013
  3. 山村亮介、坂本恵利奈、寺田芳樹、阪本親彦、小坂さおり、青山泰孝、平井　学、太田健介、日野雅之. 輸血後鉄過剰症に対する経口鉄キレート剤(deferasirox)の使用経験. 日本輸血細胞治療学会誌 58:770-773, 2013
  4. 中前博久、中根孝彦、日野雅之. 造血幹細胞移植時の心筋障害. 田村和夫編　血液疾患治療に伴う合併症対策　医学ジャーナル社 pp 180-189, 2013
  5. 吉田全宏、金島　広、中尾隆文、小川吉彦、日野雅之、中根孝彦、太田忠信、 久村岳央、間部賢寛、山村亮介、山根孝久. エルトロンボパグを使用した難治性特発性血小板減少性紫斑病の後方視的検討. 臨床血液 54:444-450, 2013
  6. 南野　智、萩原潔通、坂部真奈美、岡村浩史、稲葉晃子、永田友貴、西本光孝、康　秀男、中尾吉孝、中根孝彦、中前博久、下野太郎、日野雅之. 中枢性尿崩症を合併した染色体-7とinv(3)(q21q26.2)を有する急性骨髄性白血病. 臨床血液 54:397-402, 2013
  7. 日野雅之、中前博久、梅本由香里. 末梢血幹細胞採取. 東條有伸編　G-CSFの基礎と臨床　医学ジャーナル社 pp 175-186, 2013
  8. 間部賢寛、西本光孝、伊藤和博、岡村浩史、備後真登、吉田全宏、井上敦司、相本瑞樹、林　良樹、康　秀男、中根孝彦、中前美佳、寺田芳樹、中前博久、中尾隆文、高　起良、平井　学、中尾吉孝、山根孝久、日野雅之. 同種骨髄移植後に急性横断性脊髄炎を合併した急性リンパ性白血病. 癌と化学療法 40:529-532, 2013
  9. 中村桂子、高島　勉、日野雅之、藤岡一也、武田節子、荻澤佳奈、川尻成美、小野田尚佳、石川哲郎、平川弘聖. 乳腺に再発した急性骨髄性白血病の2症例. Jpn J Med Ultrasonics 40,297-302, 2013

工藤 新三

  1. 樽井亜紀子、田原正恵、岡本綾子、李真由美、山崎仁美、中野妙子、高島勉、工藤新三 抗がん剤の暴露予防の定着に向けた現状と課題 癌と化学療法 40、ｐ.1512-1524 2013

中尾 吉孝

  1. 中尾 吉孝, 松田 泰範, 下村 祥子, 鶴田 理恵, 柏木 伸一郎, 野田 諭, 小野田 尚佳, 平川 弘聖. 【甲状腺未分化癌の臨床】 甲状腺未分化癌の臨床像　緩和医療介入の実際. 日本内分泌・甲状腺外科学会雑誌 2013;30:182-186.
  2. 南野 智, 中前 博久, 桑村 幸伸, 石村 栄治, 坂部 真奈美, 稲葉 晃子, 康 史朗, 吉村 卓朗, 西本 光孝, 林 良樹, 寺田 芳樹, 中根 孝彦, 康 秀男, 中尾 吉孝, 大澤 政彦, 日野 雅之. 管内増殖性糸球体腎炎を合併した血管免疫芽球性T細胞性リンパ腫. 臨床血液 2013;54:658-663
  3. 南野 智, 萩原 潔通, 坂部 真奈美, 岡村 浩史, 稲葉 晃子, 永田 友貴, 西本 光孝, 康 秀男, 中尾 吉孝, 中根 孝彦, 中前 博久, 下野 太郎, 日野 雅之. 中枢性尿崩症を合併した染色体-7とinv(3)(q21q26.2)を有する急性骨髄性白血病. 臨床血液 2013;54:397-402

2012

英文

鈴村　倫弘

  1. Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, Hirata K;Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population; Osaka City Medical Journal 58:25-34
  2. Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Matsuura K, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, Nakai T, Hirata K ;Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer ; BMC Cancer　 12:568